

Serial No. 09/833,407 Amendment and Response to Restriction Requirement December 23, 2002

REPLACEMENT CLAIM SET

1. A compound of the formula

or its pharmaceutically acceptable salt or prodrug.

2. A compound of the formula:

or its pharmaceutically acceptable salt or prodrug.



Serial No. 09/833,407 Amendment and Response to Restriction Requirement December 23, 2002

- 4. A method for increasing high density lipoprotein cholesterol level in a host comprising administering an effective amount of the compound of claim1.
- 5. A method to improve the functionality of circulating high density lipoprotein in a host, comprising administering an effective amount of the compound of claim 1.
- 6. A method for increasing high density lipoprotein cholesterol level in a host comprising administering an effective amount of the compound of claim 2
- 7. A method to improve the functionality of circulating high density lipoprotein in a host, comprising administering an effective amount of the compound of claim 2.
- 69. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of

or a pharmaceutically acceptable salt thereof.

- 70. The pharmaceutical composition of claim 69 further comprising an IBAT inhibitor.
- 71. The pharmaceutical composition of claim 69 further comprising a statin.
- 72. The pharmaceutical composition of claim 71 wherein the statin is selected from the group consisting of lovastatin, simvastitin, pravastatin, fluvastatin, and atorvastatin.
- 73. The pharmaceutical composition of claim 69 further comprising a CETP inhibitor.
- 74. The pharmaceutical composition of claim 69 further comprising a fibrate.
- 75. The pharmaceutical composition of claim 69 further comprising nicotinic acid.



- 76. The pharmaceutical composition of claim 69 further comprising a compound selected from group consisting of probucol, nicotinic acid, platelet aggregation inhibitors, aspirin, coumadin, varapmil, diltiazem, nifedipine, an ACE inhibitor, captopril enalopril, propanalol, terbutalol, labetalol, ibuprofen, indomethacin, fenoprofen, mefenamic acid, flufenamic acid, sulinda, and a corticosteroid.
- 77. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of

or a pharmaceutically acceptable salt thereof.

- 78. The pharmaceutical composition of claim 77 further comprising a statin.
- 79. The pharmaceutical composition of claim 78 wherein the statin is selected from the group consisting of lovastatin, simvastitin, pravastatin, fluvastatin, and atorvastatin.
- 80. The pharmaceutical composition of claim 77 further comprising a CETP inhibitor.
- 81. The pharmaceutical composition of claim 77 further comprising a fibrate.
- 82. The pharmaceutical composition of claim 77 further comprising nicotinic acid.
- 83. The pharmaceutical composition of claim 77 further comprising a compound selected from group consisting of probucol, nicotinic acid, platelet aggregation inhibitors, aspirin, coumadin, varapmil,

\





Serial No. 09/833,407 Amendment and Response to Restriction Requirement December 23, 2002

diltiazem, nifedipine, an ACE inhibitor, captopril enalopril, propanalol, terbutalol, labetalol, ibuprofen, indomethacin, fenoprofen, mefenamic acid, flufenamic acid, sulinda, and a corticosteroid.

- 84. A method to treat a cardiovascular disease in a subject, which method comprises administering to said subject a therapeutically-effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
- 85. The method of claim 84 wherein the cardiovascular disease is atherosclerosis.
- 86. The method of claim 84 wherein the cardiovascular disease is hypercholesterolemia.
- 87. A method to treat a cardiovascular disease in a subject, which method comprises administering to said subject a therapeutically-effective amount of a compound of claim 2 or a pharmaceutically acceptable salt thereof.
- 88. The method of claim 87 wherein the cardiovascular disease is atherosclerosis.
- 89. The method of claim 87 wherein the cardiovascular disease is hypercholesterolemia.
- 90. The method of claim 4 wherein the host is a human.
- 91. The method of claim 5 wherein the host is a human.
- 92. The method of claim 6 wherein the host is a human.
- 93. The method of claim 7 wherein the host is a human.
- 94. The method of claim 84 wherein the subject is a human.
- 95. The method of claim 87 wherein the subject is a human.

Describ